Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Building A Blockbuster

A deep dive into the dynamics of blockbuster drugs.

READ NOW

Featured Stories


Merck & Co. To Enter Ophthalmology With EyeBio Buyout

Veteran developers stay on to accelerate development of potential first-in-class drug to challenge Bayer/Regeneron’s Eylea and Roche’s Vabysmo in a deal worth up to $3bn.

Clinical Trials Commercial Companies

Corcept’s Coup De GRACE

The follow-on Cushing’s product relacorilant has hit in Phase III, and is forecast to lead the market – eventually.

Clinical Trials Commercial Companies

Stock Watch: All Bayer’s Roads Lead To Unpalatable

Investors reacted quite differently to Bayer’s first-quarter results and those of its licensing partner Regeneron. There are sound reasons for this. It seems unlikely that one will help the other.

Stock Watch Sales & Earnings Strategy

Asia Spotlight

'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o

Faster, more powerful and able to handle voices and visual images, newly released AI platform GPT-4o could potentially accelerate many tasks currently handled by pharma firms' medical affairs professionals, who are exploring ways to keep themselves relevant while embracing the unprecedented technology, DIA China hears.

Artificial Intelligence China

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan

Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.

Financing Growth

Pipeline Watch: Five Approvals And 19 Phase III Read-Outs

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout

Plus deals involving Immunis/Toray, AstraZeneca/Nona, Swixx/Biopas, Deimos/G1, Serum Institute of India/IntegriMedical/ImmunityBio plus tech transfer agreements and deals in brief.

Deal Watch Business Strategies

Executives On The Move: Ocular Therapeutix Hooks ChIef Medical Officer From Beacon

Recent moves in the industry include C-suite shuffle at Senti Biosciences, plus BioMarin Pharmaceutical gets new chief commercial officer.

Leadership Executive Changes
Interviews

China Biotech CEO Interview: Starting A CNS Venture In An Economic Downturn

From Wyeth/Pfizer to Jiangsu Hengrui to IMab to starting her own biotech, Joan Huaqiong Shen has seen many ups and downs of drug development in China. She sat down with Scrip on the sidelines of the recent DIA China meeting to discuss her latest startup devoted to novel small molecules to treat schizophrenia and epilepsy and a gene therapy for ALS.

China Research & Development

AstraZeneca Advancing Respiratory Aspirations In China

The company is adopting a two-pronged strategy to capitalize on its presence in the country to expand the market for its inhaled therapies and biologics for asthma and COPD.

China Respiratory

Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Emerging Company Profile Biologics

AstraZeneca Confident Of Cementing Lead In Respiratory

The UK major’s head of respiratory and immunology, Pablo Panella, tells Scrip that AstraZeneca’s well established presence in the field “gives us an edge.”

Respiratory Clinical Trials
See All
Graphics

Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

Companies Deals

Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?

Scrip analyzed data on top-selling drugs to see how long it takes to surpass $1bn in revenues and grow into $5bn and even $10bn brands.

Launches Commercial

Blockbusters By Indication: More Begets More

A Scrip analysis of the industry’s top-selling drugs examines the power of indication expansion to drive revenue growth.

Launches Business Strategies

The Life Of A Blockbuster

The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs to see which are forecast to make the most at peak and over a 14-year time horizon.

Launches Business Strategies
See All
Recent Stories

Bristol Opts In On Second Neuro Candidate Under Prothena Alliance

Neither the mechanism nor indication is disclosed, but BMS is paying $80m up front for global rights to PRX019, which one analyst speculated might be an Alzheimer’s candidate.

Deals Business Strategies

Glenmark Initiates US Plant Cutback, Pins Hopes On gFlovent, Other Filings

Glenmark impairs oral solid dosage and nebulizer blocks at US manufacturing site amid tough market conditions. Can the firm's thrust on injectables and new respiratory filings including for generic Flovent, alongside leadership change, lift the US business?

Commercial Compliance

First Results Keep AstraZeneca’s Hopes High For Oral PCSK9 Inhibitor

AstraZeneca is looking to speed AZD0780 into Phase III development after it achieved a 78% total LDL cholesterol reduction in a Phase I study when used in combination with rosuvastatin. The firm needs to play catch up with its oral rivals.

Clinical Trials Companies

China Approval For Akeso’s Bispecific But ASCO Data Unnerve Investors

Ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 54% versus placebo in EGFR-mutated, non-squamous NSCLC after failed EGFR inhibitor treatment. However, the progression-free survival data did little to satisfy investors’ demand for clear benefits versus competitors. 

China Approvals

China Biotech CEO Interview: Starting A CNS Venture In An Economic Downturn

From Wyeth/Pfizer to Jiangsu Hengrui to IMab to starting her own biotech, Joan Huaqiong Shen has seen many ups and downs of drug development in China. She sat down with Scrip on the sidelines of the recent DIA China meeting to discuss her latest startup devoted to novel small molecules to treat schizophrenia and epilepsy and a gene therapy for ALS.

China Research & Development

Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy

Asahi Kasei established a US presence and expertise in renal disease when it bought Veloxis in 2020 and will expand in both areas with Calliditas’s Tarpeyo for immunoglobulin A nephropathy (IgAN).

M & A Renal

J&J Continues Atopic Dermatitis Effort With Numab Deal

Johnson & Johnson, after several prior failed R&D attempts in AD, will pay Numab $1.25bn to acquire a subsidiary and its Phase II-ready bispecific antibody for key unmet needs in the disease.

M & A Business Strategies

Insmed Planning 2025 Launch For Brensocatib In Bronchiectasis

The drug maker anticipates a smooth regulatory path and has already begun to rapidly expand its sales force across most of the US.

Clinical Trials Business Strategies

Agios Extends Cash Runway With $905m Royalty Pharma Deal

Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.

Deals Cancer

AstraZeneca And Daiichi Follow Gilead’s Lead

The partners’ antibody-drug conjugate datopotamab deruxtecan misses on overall survival, potentially limiting its market reach.

Clinical Trials Commercial

AstraZeneca Advancing Respiratory Aspirations In China

The company is adopting a two-pronged strategy to capitalize on its presence in the country to expand the market for its inhaled therapies and biologics for asthma and COPD.

China Respiratory
UsernamePublicRestriction

Register